News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
588,883 Results
Type
Article (42451)
Company Profile (349)
Press Release (546083)
Section
Business (167679)
Career Advice (2429)
Deals (30308)
Drug Delivery (102)
Drug Development (78591)
Employer Resources (148)
FDA (14343)
Job Trends (12968)
News (295882)
Policy (28491)
Tag
Academia (2655)
Alliances (42758)
Alzheimer's disease (1314)
Approvals (14283)
Artificial intelligence (147)
Bankruptcy (316)
Best Places to Work (10633)
Biotechnology (279)
Breast cancer (186)
Cancer (1370)
Cardiovascular disease (119)
Career advice (2040)
Cell therapy (295)
Clinical research (62614)
Collaboration (474)
Compensation (195)
COVID-19 (2521)
C-suite (119)
Data (1388)
Diabetes (169)
Diagnostics (5646)
Earnings (60360)
Employer resources (136)
Events (87966)
Executive appointments (402)
FDA (14991)
Funding (429)
Gene therapy (212)
GLP-1 (630)
Government (4182)
Healthcare (17183)
Infectious disease (2613)
Inflammatory bowel disease (121)
Interviews (519)
IPO (14108)
Job creations (2754)
Job search strategy (1678)
Layoffs (412)
Legal (6019)
Lung cancer (208)
Manufacturing (192)
Medical device (11007)
Medtech (11011)
Mergers & acquisitions (16349)
Metabolic disorders (468)
Neuroscience (1659)
NextGen Class of 2024 (5956)
Non-profit (4112)
Northern California (1581)
Obesity (261)
Opinion (210)
Parkinson's disease (100)
Patents (118)
People (53422)
Phase I (19627)
Phase II (27666)
Phase III (20604)
Pipeline (512)
Postmarket research (2389)
Preclinical (8303)
Radiopharmaceuticals (246)
Rare diseases (275)
Real estate (4485)
Regulatory (19721)
Research institute (2267)
Resumes & cover letters (359)
Southern California (1413)
Startups (3170)
United States (14035)
Vaccines (540)
Weight loss (197)
Date
Today (34)
Last 7 days (567)
Last 30 days (2320)
Last 365 days (33619)
2024 (33429)
2023 (37498)
2022 (48412)
2021 (52024)
2020 (50011)
2019 (42546)
2018 (32073)
2017 (29661)
2016 (28191)
2015 (32973)
2014 (25388)
2013 (20574)
2012 (21779)
2011 (22687)
2010 (20427)
Location
Africa (737)
Arizona (137)
Asia (35841)
Australia (7129)
California (3610)
Canada (1382)
China (288)
Colorado (158)
Connecticut (156)
Europe (80332)
Florida (488)
Georgia (118)
Illinois (346)
Indiana (201)
Maryland (598)
Massachusetts (2730)
Michigan (164)
Minnesota (250)
New Jersey (1040)
New York (1022)
North Carolina (704)
Northern California (1581)
Ohio (130)
Pennsylvania (823)
South America (1012)
Southern California (1413)
Texas (497)
Utah (108)
Washington State (372)
588,883 Results for "calliditas therapeutics formerly known as pharmalink".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Calliditas Therapeutics to Attend Conferences in April
Calliditas Therapeutics AB today announced that its management will be attending the following upcoming investor and industry conferences.
April 9, 2024
·
1 min read
Deals
Asahi Kasei to Acquire Calliditas Therapeutics AB to Accelerate Growth as a Global Healthcare Company
Asahi Kasei Corp. announces that it will offer the shareholders of Calliditas Therapeutics AB to acquire the shares of the pharmaceutical company Calliditas for the purpose of making Calliditas a wholly-owned subsidiary of Asahi Kasei through a voluntary tender offer for Calliditas.
May 28, 2024
·
7 min read
Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress
Calliditas Therapeutics AB today announced the presentations of an additional efficacy analysis of Nefecon (TARPEYO ® (budesonide) delayed release capsules)) as well as a real-world analysis of the use of systemic glucocorticoids (SGC) in IgA nephropathy (IgAN).
May 28, 2024
·
8 min read
Deals
Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation
The Board of Directors of Calliditas Therapeutics AB unanimously recommends that the shareholders and holders of American Depositary Shares of Calliditas Therapeutics AB accept the public tender offer by Asahi Kasei Corporation.
May 28, 2024
·
24 min read
Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm
Calliditas Therapeutics AB today announced upcoming data presentations and a sponsored symposium at the 61st European Renal Association (ERA) Congress, in Stockholm, Sweden on May 23 - 26, 2024.
May 15, 2024
·
6 min read
Business
Calliditas Therapeutics’ 2023 Annual Report Published
Calliditas Therapeutics AB, announces that the Annual Report for 2023 now is available at the company’s website.
April 24, 2024
·
3 min read
Press Releases
Calliditas Therapeutics to Present Four Abstracts at American Society of Nephrology (ASN) Kidney Week 2024
October 17, 2024
·
6 min read
Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires
Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) (“Calliditas”), today announced upcoming data presentations, as well as a sponsored symposium at the International Society of Nephrology’s World Congress of Nephrology.
April 8, 2024
·
8 min read
Deals
Asahi Kasei Offers $1.1B for Swedish Pharma Calliditas Therapeutics
The potential purchase by the Japanese conglomerate could secure access to Calliditas’ IgA nephropathy therapy Tarpeyo, which won the FDA’s full approval in December 2023.
May 28, 2024
·
2 min read
·
Tyler Patchen
Business
PharmaLink Inc. and Recall Results, Inc. Announce Strategic Partnership to Enhance Drug Safety and Recall Efficiency
PharmaLink Inc., a national leader in pharmaceutical reverse distribution, and Recall Results, a prominent provider of comprehensive recall management and support services, today announced a strategic partnership aimed at enhancing drug safety and recall efficiency in the pharmaceutical industry.
April 26, 2024
·
4 min read
1 of 58,889
Next
